14 June 2019

Hypercholesterolemia is a major risk factor for cardiovascular disease. Statins are the most widely used cholesterol-lowering drugs. However, despite treatment with statins, many patients with elevated cholesterol levels will still develop cardiovascular disease. Currently it is apparent that not only cholesterol but also the immune system plays an important role in the development of atherosclerosis, but how cholesterol and the immune system interact is still unravelled.

Siroon Bekkering, theme Vascular damage, with colleagues from Amsterdam and Rotterdam investigated the activity of part of the immune system in individuals with and without high cholesterol levels. It appeared that specific immune cells in the blood (‘monocytes’) were more activated in patients with high cholesterol levels than in individuals with normal cholesterol levels; these cells produced more inflammatory molecules that are important in the development of cardiovascular disease. Subsequently, the patients with high cholesterol were treated with statins to lower their cholesterol levels and the same measurements were repeated three months later. Importantly, despite cholesterol lowering, the hyperactivity of the immune cells did not decrease at all.

Niels Riksen, theme Vascular damage, coordinator of the project states that “we thus observed that these immune cells appear to ‘remember’ the high cholesterol, they once were exposed to. The finding that monocytes can remember previous exposures has only recently been discovered, and has been termed ‘trained immunity’, and this is the first study to demonstrate this in patients.” According to Riksen it would be interesting to investigate now how long this memory lasts and also whether the hyperactivity of the monocytes can be reduced by other drug types, such as anti-inflammatory drug.

Source: Bekkering S, Stiekema LCA, Bernelot Moens S, Verweij SL, Novakovic B, Prange K, Versloot M, Roeters van Lennep JE, Stunnenberg H, de Winther M, Stroes ESG, Joosten LAB, Netea MG, Riksen NP. Treatment with statins does not revert trained immunity in patients with familial hypercholesterolemia. Cell Metab 2019 [in press]

Related news items

COVID-19 associated coagulopathy - lessons after 1 year

17 May 2021 Jenneke Leentjens, Saskia Middeldorp, and colleagues, published a review on the current knowledge of COVID-19 associated coagulopathy and the role of antithrombotic therapies in the Lancet Haematology. read more

Set7 regulates enhanced cytokine production in trained immunity in vitro

28 April 2020 Postdoc Sam Keating and colleagues from the group of Niels Riksen, theme Vascular damage, revealed Set7 as a key regulator of trained immunity. They have published their findings in Cell Reports.  read more

Catecholamines induce trained immunity in monocytes in vitro and in vivo

10 April 2020 Niels Riksen and colleagues contributed data in Circulation Research, to the understanding of pathways driving inflammatory changes in conditions characterized by high catecholamine levels, and proposed that trained immunity underlies the increased cardiovascular event rate in PHEO patients. read more

Dutch National Postdoc award for Siroon Bekkering

29 November 2019 Siroon Bekkering, theme Vascular damage, will use the prize money (€10,000) for her follow-up research into the memory of the innate immune system of patients with cardiovascular diseases. read more

RIMLS PhD grants awarded to eight RIMLS (j)PI's

12 September 2019 Recently, RIMLS held an internal call for Radboudumc junior researcher (PhD) positions. Congratulations for all the awardees and all the best in conducting the research projects. read more